Hospital
Ihc Health Services, INC.
Ihc Health Services, INC. was paid $17.19M by Medicaid between Jan 2018 and Nov 2024, across 145 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 74% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES, INC.
AMERICAN FORK, UT 84003
AMERICAN FORK, UT 84003
33aNPI1912014358assigned 08/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.19M
24GClaims271,618
24DCodes billed145
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#5 of 26
Median peer was paid$6.14M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,248 | $2.24M | |
| 2019 | 41,561 | $2.41M | |
| 2020 | 50,101 | $3.31M | |
| 2021 | 61,563 | $4.27M | |
| 2022 | 59,159 | $4.36M | |
| 2023 | 12,480 | $455K | |
| 2024incomplete | 5,506 | $149K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 74% | 30,801 | 15,287 | $12.71M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 11,304 | 9,342 | $525K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 20,738 | 17,210 | $523K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.0% | 10,368 | 9,131 | $350K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.9% | 12,972 | 11,358 | $333K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 2,931 | 2,411 | $295K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 1,913 | 1,783 | $248K |
| 80050 | General health panel | <1% | 1,800 | 1,693 | $149K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 5,615 | 4,988 | $104K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,484 | 2,276 | $100K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,159 | 1,588 | $94K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,503 | 2,018 | $87K |
133 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,913 | $76K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,816 | $75K |
| 85027 | <1% | 1,880 | $69K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,079 | $66K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,237 | $59K |
| 81001 | <1% | 8,263 | $58K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,488 | $54K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,577 | $49K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,563 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,331 | $47K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,950 | $47K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,578 | $47K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,326 | $43K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,363 | $43K |
| 74018 | <1% | 911 | $40K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,812 | $40K |
| 80053 | Comprehensive metabolic panel | <1% | 16,878 | $38K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,338 | $37K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,851 | $36K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,377 | $34K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 836 | $33K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,096 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,270 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 221 | $29K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 291 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,498 | $27K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,528 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 901 | $27K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,931 | $24K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 169 | $22K |
| 81025 | <1% | 1,007 | $22K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,445 | $21K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 300 | $20K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 784 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 648 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,548 | $16K |
| 84702 | <1% | 1,856 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,316 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,849 | $12K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,266 | $11K |
| 87631 | <1% | 157 | $11K | |
| 96376 | <1% | 3,081 | $11K | |
| 82247 | <1% | 1,794 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,949 | $10K |
| 84703 | <1% | 2,369 | $10K | |
| 86901 | <1% | 683 | $8K | |
| 81003 | <1% | 314 | $8K | |
| 84484 | <1% | 2,307 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,183 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,234 | $8K |
| 73630 | <1% | 162 | $7K | |
| 83690 | <1% | 5,590 | $7K | |
| 97161 | <1% | 62 | $7K | |
| 87081 | <1% | 271 | $7K | |
| 87186 | <1% | 838 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 29 | $6K |
| 85379 | <1% | 1,336 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 308 | $5K |
| 80061 | Lipid panel | <1% | 1,410 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 323 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 204 | $4K |
| 73610 | <1% | 62 | $3K | |
| 85610 | <1% | 1,049 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,280 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,018 | $3K |
| 85651 | <1% | 1,753 | $3K | |
| 93971 | <1% | 119 | $3K | |
| 84439 | <1% | 1,237 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 27 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 372 | $2K |
| 86140 | <1% | 2,886 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 829 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 50 | $2K |
| 76642 | <1% | 128 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 90 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 879 | $2K |
| 83735 | <1% | 1,262 | $2K | |
| 73110 | <1% | 26 | $1K | |
| 73130 | <1% | 20 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 107 | $1K |
| 80164 | <1% | 126 | $1K | |
| 76801 | <1% | 31 | $1K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 12 | $982.06 |
| 87807 | <1% | 12 | $974.26 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 393 | $856.26 |
| 83605 | <1% | 1,379 | $585.46 | |
| 86850 | <1% | 200 | $583.35 | |
| 73562 | <1% | 12 | $564.12 | |
| 82570 | <1% | 117 | $444.96 | |
| 73030 | <1% | 19 | $418.40 | |
| 82550 | <1% | 30 | $384.24 | |
| 82565 | <1% | 95 | $359.47 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $344.28 |
| 82805 | <1% | 14 | $339.27 | |
| 84146 | <1% | 96 | $289.91 | |
| 84481 | <1% | 15 | $288.69 | |
| 72100 | <1% | 13 | $245.20 | |
| 83516 | <1% | 27 | $229.15 | |
| 85007 | <1% | 448 | $218.57 | |
| 85730 | <1% | 129 | $169.18 | |
| 84466 | <1% | 58 | $159.45 | |
| 87040 | <1% | 819 | $149.63 | |
| 82728 | <1% | 79 | $146.25 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 482 | $127.22 |
| 83880 | <1% | 302 | $118.95 | |
| 84156 | <1% | 51 | $107.13 | |
| 86900 | <1% | 85 | $105.16 | |
| 80178 | <1% | 13 | $100.40 | |
| 87088 | <1% | 638 | $96.99 | |
| 82607 | <1% | 121 | $88.19 | |
| 82248 | <1% | 16 | $71.10 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 36 | $52.24 |
| J3490 | Unclassified drugs | <1% | 44 | $36.58 |
| 84132 | 0% | 38 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 29 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 106 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 154 | $0.00 |
| 83615 | 0% | 176 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 31 | $0.00 |
| 88304 | 0% | 40 | $0.00 | |
| 90686 | 0% | 57 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 27 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 26 | $0.00 |
| 87070 | 0% | 18 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 13 | $0.00 |
| 83540 | 0% | 61 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 144 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 13 | $0.00 |
| 84100 | 0% | 18 | $0.00 | |
| 87075 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $68.77M |
| Ihc Health Services, INC. | St George, UT | $65.78M |
| Ihc Health Services INC | Ogden, UT | $54.08M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services INC | Logan, UT | $25.34M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services INC | Riverton, UT | $15.31M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.